Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech ...

An announcement from Recursion Pharmaceuticals ( (RXRX)) is now available. On May 6, 2026, Recursion reported first-quarter 2026 results and business updates, highlighting multiple pipeline milestones ...

Recursion Pharmaceuticals ( (RXRX)) just unveiled an announcement. On April 28, 2026, Recursion Pharmaceuticals announced that founder and Chair of the Board Christopher Gibson, Ph.D., informed the ...

Menlo Ventures today announced $3 billion in new capital to back promising AI companies at every stage, across the AI stack, from infrastructure and frontier technologies to AI-native applications in ...

When AI Becomes a Self-Improving Strategic Asset The Battlefield That Exists Only in Code Imagine a commander who never ...

You can so much with DNS filtering.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

One of the world’s leading artificial intelligence companies has implored the industry to pause development on AI, because the latest models could be reaching a tipping point where they become capable ...

On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...